The FDA warned an asthma drug could induce despair. Many were never told
In 2020, the Food and Drug Administration (FDA) issued a stark warning about the asthma and allergy drug Singulair, indicating potential side effects such as aggression and suicidal thoughts. However, the warning had limited impact, as the drug was still prescribed to 12 million people in the United States in 2022. Children, who face higher risks, continued to use the drug, with 1.6 million prescriptions. The FDA's handling of Singulair highlights gaps in addressing side effects from long-approved medications and in effectively warning the public and doctors. Despite issuing a warning label, the FDA did not mandate education for doctors regarding the drug's side effects. Some patients only became aware of the risks through online support groups, emphasizing the need for improved communication about medication risks.
For more news & updates, check out the link given below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.